Cardiomyopathy - Treatment with lithium or amphotericin B Factor
Last reviewed for CCPS 18 July 2007.
Investigative Documents
Medical Report - Treatment with Lithium or Amphotericin B - Cardiomyopathy [MR9385]
Preliminary questions [38353]
there is some evidence that being treated with lithium or amphotericin B may be a factor in the development or worsening of the condition under consideration.38355 the veteran was being treated with lithium or amphotericin B for treatment of an illness or injury which is identifiable.
38356 — the veteran has established the causal connection between being treated with lithium or amphotericin B and operational service for cardiomyopathy.
for the identified illness or injury, the veteran was being treated with lithium or amphotericin B within the seven days before the clinical onset of the condition under consideration.38357 — the veteran has established the causal connection between being treated with lithium or amphotericin B and operational service for the clinical onset of cardiomyopathy.
or
the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service. the condition under consideration permanently worsened. for the identified illness or injury, the veteran was being treated with lithium or amphotericin B within the seven days before the clinical worsening of the condition under consideration.38358 — the veteran has established the causal connection between being treated with lithium or amphotericin B and operational service for the clinical worsening of cardiomyopathy.
Clinical onset and operational service [38357]
38361 — the identified illness or injury, for which the veteran was being treated with lithium or amphotericin B, is causally related to operational service.
Clinical worsening and operational service [38358]
38361 — the identified illness or injury, for which the veteran was being treated with lithium or amphotericin B, is causally related to operational service.
the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the veteran was being treated with lithium or amphotericin B, is causally related.